LAZARD/CYRUS-KAPADIA
Lazard Ltd (NYSE: LAZ) announced today that it has named Cyrus Kapadia as Chief Executive Officer (CEO) of Lazard Investment Banking in the UK and William Rucker, CEO of the business since 2004, as Chairman, effective immediately. Archie Norman, Chairman of the business since 2013, will continue to serve Lazard as a Special Adviser to Lazard’s CEO.
“William has successfully built and led one of our firm’s most important investment banking franchises in his career at Lazard over the past 30 years,” said Kenneth M. Jacobs, Chairman and CEO of Lazard. “This transition will allow him to focus his efforts as a preeminent adviser to our UK clients.”
“Cyrus is an experienced and trusted adviser to clients, and has played a key role in the recruitment and retention of our people, as well as the evolution, technology advancements and diversification of our business in the UK,” said Peter Orszag, CEO of Lazard Financial Advisory. “In his new role, he will focus on the continued growth of our UK business and on achieving even closer cooperation globally on behalf of our clients.”
“Archie has made invaluable contributions to the firm as Chairman of UK Investment Banking for the past six years, and we thank him for all that he has accomplished,” said Mr. Jacobs. “We look forward to continuing to benefit from his sage advice.”
Mr. Kapadia, most recently Deputy Head of UK Investment Banking, joined Lazard in 1996. He has worked with clients across numerous industry sectors and leads the Technology, Media and Telecommunications Advisory Group in London, one of Lazard’s most active teams in the UK. Mr. Kapadia has had a wide range of corporate finance experience including providing advice to many of the UK's largest companies and private equity sponsors.
Mr. Rucker has served as CEO of Lazard’s Investment Banking business in the UK for the past 15 years. He began his investment banking career at Lazard in 1987. As Chairman, he will continue to work closely with Mr. Kapadia and the UK Investment Banking team, focusing in particular on key client relationships and growth initiatives.
Mr. Norman, a Senior Adviser for Lazard Investment Banking in the UK since 2003, has served as Chairman of Lazard UK Investment Banking since 2013. He was appointed Chairman of Marks & Spencer in October 2017.
Lazard in London is a principal office of the firm’s global network. It has been a major presence in London's financial center since 1877, and added institutional asset management services in 1953. Located in the heart of Mayfair, it is one of Lazard's largest offices, with senior professionals representing all of Lazard's advisory services.
Lazard’s UK Investment Banking business has advised or continues to advise on a number of significant transactions. These include advising Blackstone, KIRKBI and the Canada Pension Plan Investment Board on its acquisition of Merlin Entertainments; Saputo on its acquisition of Dairy Crest; Takeaway.com on its acquisition of JustEat, PLC; WPP on the sale of 60% of Kantar to Bain Capital; Smith & Nephew on its acquisition of Osiris Therapeutic; Daily Mail Trust Group on the sale of its shares in Euromoney PLC; and Merck on its global alliance with GSK.
About Lazard
Lazard, one of the world’s preeminent financial advisory and asset management firms, operates from 43 cities across 27 countries in North America, Europe, Asia, Australia, Central and South America. With origins dating to 1848, the firm provides advice on mergers and acquisitions, strategic matters, restructuring and capital structure, capital raising and corporate finance, as well as asset management services to corporations, partnerships, institutions, governments and individuals. For more information about Lazard, please visit www.lazard.com . Follow Lazard at @Lazard.
LAZ-FAPE
View source version on businesswire.com: https://www.businesswire.com/news/home/20190909005898/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Pilots to Profit: NTT DATA's 2026 Global AI Report Shows How Top Performers Turn AI Vision Into Value8.12.2025 14:00:00 CET | Press release
Study reveals how the top 15% of companies are 2.5x more likely to post >10% revenue growth and over 3x more likely to achieve ≥15% profit margins from AI deployments NTT DATA, a global leader in AI, digital business and IT services, today released the 2026 Global AI Report: A playbook for AI leaders. The playbook is based on the company’s new benchmark research and reveals how “AI leaders” are separating from competitors through strategy and execution. The analysis is based on a survey of 2,567 senior executives across 35 countries and 15 industries. Only 15% of participating organizations qualified as “AI leaders,” defined by clear AI strategies, mature operating models and focused execution. These leaders report significantly higher revenue growth and profit margins than other organizations. “AI accountability now belongs in the boardroom and demands an enterprise-wide agenda,” said Yutaka Sasaki, President and CEO, NTT DATA Group. “Our research shows that a small group of AI leader
AdvanCell Receives First Delivery of High-Activity Thorium-228, Highlighting a Unique Industry Capability and Expertise Essential to Scaling Lead-212 Production for Targeted Alpha Therapies8.12.2025 14:00:00 CET | Press release
Thorium-228 (228Th) is the parent isotope and key starting material to produce the alpha-emitter Lead-212 (212Pb) The established capability to receive and process high-activity 228Th, provides a key competitive advantage in scaling up 212Pb production to support the rapid advancement of 212Pb-ADVC001 (ADVC001) clinical development and the expanding pipeline The received 228Th will be processed into sources for our proprietary generator and installed in production systems first in Australia and subsequently in the US, as part of the planned expansion AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced it has received the first delivery of high-activity 228Th, the parent isotope of 212Pb and a key starting material to produce the alpha-emitter 212Pb, used to manufacture ADVC001, the company’s lead asset, and other 212Pb-based radioligand therapies in the pipeline. This delivery marks a major milestone for the
BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia8.12.2025 14:00:00 CET | Press release
Multiple long-term follow-up studies confirm BRUKINSA’s superior efficacy and favorable tolerability versus ibrutinib in relapsed or refractory CLLAdditional ASH data from investigational BTK degrader, BGB-16673, highlight potential first- and best-in-class activity with durable responses in heavily pretreated patients with CLL BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) innovation by showcasing the depth, quality, and momentum of its hematology portfolio at the 67th ASH Annual Meeting and Exposition in Orlando, Florida. The totality of BeOne’s ASH data reinforce BRUKINSA® (zanubrutinib) as the foundational Bruton’s tyrosine kinase inhibitor (BTKi) of choice. “At ASH 2025, we will present new data from across our CLL franchise, highlighting both the strength of BRUKINSA and the potential of BGB-16673,” said Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology,
Pink Changing Lives®: Mary Kay Builds 11th Preschool in Sri Lanka, Turning a Dream Into Thousands of New Beginnings8.12.2025 14:00:00 CET | Press release
Each year, Mary Kay supports causes that enrich millions of women’s lives globally, including access to education Mary Kay Inc., a global champion for women’s empowerment, is turning pink into purpose through its Pink Changing Lives® Program to raise awareness and funds to support life-changing programs advancing cancer research, support survivors of domestic violence, protect our planet’s most precious resources, and create opportunities that help women and their families thrive. Since 1996, the multi-faceted Pink Changing Lives® Program has donated over $230 million in monetary and in-kind donations to improve the lives of women and their families in communities around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208554750/en/ Mary Kay Inc., a global champion for women’s empowerment, is turning pink into purpose through its Pink Changing Lives® Program to raise awareness and funds to support life-changing p
IonQ Expands in EU With Slovakia’s First National Quantum Communication Network8.12.2025 13:05:00 CET | Press release
Partnering with the Slovak Academy of Sciences, IonQ bolsters national security and European quantum communications infrastructure IonQ (NYSE: IONQ), the world’s leading quantum company, through its subsidiary ID Quantique (IDQ), today announced the deployment of Slovakia’s first national quantum communication network. Developed in partnership with the Institute of Physics, Slovak Academy of Sciences (IPSAS), the new system features a resilient hybrid architecture designed to strengthen the country’s cybersecurity infrastructure and support Europe’s quantum digital programs. The Slovak Quantum Communication Infrastructure (skQCI) project represents a major milestone in Slovakia’s contribution to the European Quantum Communication Infrastructure (EuroQCI) initiative, which seeks to establish a secure quantum-resistant communication backbone covering all European Union (EU) member states and territories. By integrating quantum-safe technologies at a national scale, Slovakia will directly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom